Recruiting
Phase 2

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Sponsor:

Adrienne G. Waks

Code:

NCT06100874

Conditions

Her 2 Positive Breast Cancer

Breast Cancer Female

Breast Cancer Metastatic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan

Trastuzumab

Trastuzumab and Hyaluronidase-oysk

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information